Low-dose emapalumab combined with chemotherapy for adult patients with Epstein–Barr virus-associated hemophagocytic lymphohistiocytosis
Transplant Immunology · 2025
DOI: 10.1016/j.trim.2024.102162 ↗Kurz gefasst
Fallbericht in der Zeitschrift Transplant Immunology, 2025. Verfasst von Wenjuan Zhu und 11 weiteren Autor:innen. Beteiligte Einrichtung: National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, Department of Hematology, The First Affiliated Hospital …. Hauptthemen laut MEDLINE: Lymphohistiocytosis, Hemophagocytic, Epstein-Barr Virus Infections, Hematopoietic Stem Cell Transplantation, Herpesvirus 4, Human. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 15 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Hemophagocytic lymphohistiocytosis (HLH) is a severe disorder with poor clinical outcomes. Use of emapalumab, an IFN-γ inhibitor, enables primary HLH control in over 85 % of affected children. However, data on emapalumab use for Epstein-Barr virus-associated HLH (EBV-HLH) are limited. This report presents the cases of three patients with EBV-HLH, highlighting the successful integration of low-dose emapalumab in combination with chemotherapy as a novel therapeutic approach for patients diagnosed with EBV-HLH. This regimen resulted in rapid disease symptom control and hematological parameter improvement and facilitated successful stem cell transplantation. This report highlights the potential of low-dose emapalumab combined with chemotherapy as an effective bridging therapy to allogenic hematopoietic stem cell transplantation in EBV-HLH patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, Department of Hematology, The First Affiliated Hospital of Soochow University, Suzhou 215000, China.
- Soochow Hopes Hematonosis Hospital, Suzhou 215000, China.
- National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, Department of Hematology, The First Affiliated Hospital of Soochow University, Suzhou 215000, China. Electronic address: wuxia…
- National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, Department of Hematology, The First Affiliated Hospital of Soochow University, Suzhou 215000, China. Electronic address: hexue…
Zitieren
APA
Zhu, W., Zhou, F., Song, Y., Zhou, S., Du, F., Zhu, Q., Wang, Z., Bai, L., Fu, J., Ma, X., Wu, X., & He, X. (2025). Low-dose emapalumab combined with chemotherapy for adult patients with Epstein–Barr virus-associated hemophagocytic lymphohistiocytosis. Transplant Immunology. https://doi.org/10.1016/j.trim.2024.102162
Vancouver
Zhu W, Zhou F, Song Y, Zhou S, Du F, Zhu Q, et al. Low-dose emapalumab combined with chemotherapy for adult patients with Epstein–Barr virus-associated hemophagocytic lymphohistiocytosis. Transplant Immunology. 2025. doi:10.1016/j.trim.2024.102162
BibTeX
@article{Zhu2025,
author = {Zhu, Wenjuan and Zhou, Fei and Song, Yue and Zhou, Shiyuan and Du, Feng and Zhu, Qian and Wang, Ziyi and Bai, Liyun and Fu, Jianhong and Ma, Xiao and Wu, Xiaojin and He, Xuefeng},
title = {Low-dose emapalumab combined with chemotherapy for adult patients with Epstein–Barr virus-associated hemophagocytic lymphohistiocytosis},
journal = {Transplant Immunology},
year = {2025},
doi = {10.1016/j.trim.2024.102162}
}
EUVIMED